exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088188 RNA Name: hsa-miR-345-5p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 100307876 End Site(bp): 100307897 External Links: hsa-miR-345-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AC011455.2 chr19 38915404 38949855 - CNBP chr3 129169484 129183922 - FAM222B chr17 28755978 28855232 - GCNT4 chr5 75025346 75052558 - GPD2 chr2 156435290 156613735 + HEG1 chr3 124965710 125055997 - IGF2BP1 chr17 48997385 49056145 + LCLAT1 chr2 30447226 30644225 + MAP3K14 chr17 45263119 45317029 - MAPK1 chr22 21754500 21867680 - RCOR1 chr14 102592649 102730561 + RIPOR1 chr16 67518418 67546788 + SARS2 chr19 38915266 38930896 - SPTBN2 chr11 66685248 66729226 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001867 chr9 86294689 86297981 - hsa_circ_0001866 chr9 86293355 86297981 - hsa_circ_0001392 chr4 3088665 3109150 + hsa_circ_0001387 chr4 1902352 1936989 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC079781.5 chr7 97851688 97972985 - GAS5 chr1 173858559 173868882 - KCNQ1OT1 chr11 2608328 2699994 - LINC01772 chr1 16460948 16468481 + NEAT1 chr11 65422774 65445540 + SNHG15 chr7 44983023 44986961 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.